Neural's Portfolio Company Hanf.com Expands Retail Footprint to Northern Germany with Two New Stores in Bielefeld and Herford
Toronto, Ontario--(Newsfile Corp. - November 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, in which it owns 30.75% int
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-11-06 8:46 AM EST | Neural Therapeutics Inc.
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025). The presentation generated exceptional interest from both the scientific a
Biotechnology, Pharmaceuticals, Health
2025-11-06 3:15 AM EST | Defence Therapeutics Inc.
Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell
Reno, Nevada--(Newsfile Corp. - November 5, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors. The additions bring together leading expertise from the worlds of medicine, science, and ethics-driven innovation as Conexeu advances its mission to pioneer collagen-based
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-05 7:00 AM EST | Conexeu Sciences Inc.
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-04 5:30 PM EST | Medexus Pharmaceuticals Inc.
Hemostemix Closes Private Placement of $461,230
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:09 PM EST | Hemostemix Inc.
Telescope Innovations Conditionally Approved for up to $3.36 M in Government Funding to Advance Lithium Processing Technology
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company") is a leader in providing intelligent automation platforms and services that accelerate chemical process development. The Company is pleased to announce that two Government of Canada funding streams totalling up to CAD $3.36 M have been formally or conditionally awarded to Telescope to support th
Technology, Chemical, Pharmaceuticals
2025-11-04 11:00 AM EST | Telescope Innovations Corp.
BioHarvest Sciences to Host Third Quarter Earnings Call on November 13 at 4:30 p.m. Eastern Time
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an inve
Biotechnology, Pharmaceuticals, Health
2025-11-04 7:30 AM EST | BioHarvest Sciences Inc.
Wellgistics Health Enters into LOI to Acquire Kare Rx Hub
Tampa, Florida--(Newsfile Corp. - November 4, 2025) - We
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Blockchain
2025-11-04 6:00 AM EST | Wellgistics Health
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models
Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce and to present today at the World ADC Conference in San Diego, USA, highly encouraging results from its latest preclinical in vivo study evaluating Accum®-Kadcyla, a novel version of Genentech/Roche's marketed ADC Kadcyla® (ado-trastuzumab
Biotechnology, Pharmaceuticals, Health
2025-11-04 3:15 AM EST | Defence Therapeutics Inc.
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 5,663,182 shares of common stock of the Company originally issued in July 2024, December 2024, Januar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 1:40 PM EST | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 7:45 AM EST | Phio Pharmaceuticals Corp.
Conexeu Sciences Appoints Miles Harrison as President & Chief Executive Officer, to Shape the Future of True Tissue Regeneration
Reno, Nevada--(Newsfile Corp. - November 3, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a pre-commercial biotechnology company redefining regenerative medicine through next-generation collagen science, announces the appointment of Miles D. Harrison as President & Chief Executive Officer of the Company. He has also been appointed to the Company's Board of Directors. At Conexeu, Miles will lead the Company's next phase of growth, advancing its first-in-class col
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-03 7:00 AM EST | Conexeu Sciences Inc.
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to share a scientific poster which demonstrates the effectiveness of X-Ray-activated Rutherrin® for numerous cancer
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-03 7:00 AM EST | Theralase Technologies Inc.
Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00
Gaithersburg, Maryland--(Newsfile Corp. - November 3, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced that it entered into a securities purchase agreement with a single investor for aggregate gross proceeds of approximately $2.5 million (the "Offering"), before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for marketing, g
2025-11-03 7:00 AM EST | Shuttle Pharmaceuticals Holdings Inc.
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment bankin
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-31 10:15 AM EDT | Phio Pharmaceuticals Corp.
Anne-Kathrin Stoller to Become New CEO at Bachem
Bubendorf, Switzerland--(Newsfile Corp. - October 31, 2025) - Ad hoc announcement pursuant to Art. 53 LR Anne-Kathrin Stoller to become new CEO at Bachem Bachem (SIX: BANB) announced today that its Board of Directors has appointed Anne-Kathrin Stoller, currently Head of Bachem Americas and previously the company's long-standing Chief Marketing Officer (CMO), as its new CEO, effective January 1, 2026. She succeeds Thomas Meier, wh
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-31 2:23 AM EDT | Bachem Holding AG
Republic Technologies Provides Corporate Updates for Q3 and Outlooks for Q4
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to provide this comprehensive news release outlining recent management updates, corporate developments, and business strategies for Q2 and Q3 2025. Management Update At the Company's Annual General and Special Meeting held on August 9, 2025, Republic announced the appointment of
Technology, Pharmaceuticals, Health
2025-10-31 2:00 AM EDT | Republic Technologies Inc.
Republic Technologies gibt Unternehmensupdates für Q3 und Ausblick auf Q4 bekannt
Vancouver, British Columbia--(Newsfile Corp. - Freitag, 31. Oktober 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (das "Unternehmen" oder "Republic") freut sich, diese umfassende Pressemitteilung zu veröffentlichen, die aktuelle Management-Updates, Unternehmensentwicklungen und Geschäftsstrategien für das zweite und dritte Quartal 2025 zusammenfasst. Management-Update Auf der Jahres- und Sonderhauptversammlung des Unternehmen
Technology, Pharmaceuticals, Health
2025-10-31 2:00 AM EDT | Republic Technologies Inc.
Hemostemix's Boots on the Ground in Florida October Update
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, today announced major progress in Flori
Biotechnology, Pharmaceuticals, Health
2025-10-30 11:29 AM EDT | Hemostemix Inc.
Herbal Dispatch Brings on Industry Veteran as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leader in cannabis distribution, is pleased to welcome Jay Wilgar, a 20-year veteran in startup management and business growth, to its team as a Strategic Advisor to the management team. Mr. Wilgar is the former CEO and Chairman of Newstrike Brands Ltd.—one of Canada's first licensed cannabis p
Pharmaceuticals, Cannabis, Cannabis Dispensary
2025-10-30 9:00 AM EDT | Herbal Dispatch Inc.